Fucithalmic1%

Fucithalmic is a bacteriostatic (and, at higher concentrations, bactericidal) antibacterial used mainly for skin and soft-tissue infections caused by susceptible Staphylococcus aureus and other Gram-positive organisms.

Established / Widely Approved Uses (Topical)

• Impetigo
• Infected eczema and infected dermatitis
• Infected minor wounds, cuts, and abrasions
• Folliculitis and furunculosis (boils)
• Secondary bacterial infection of other skin conditions

Established Use (Ophthalmic Formulation)

• Bacterial conjunctivitis (using Fucithalmic viscous eye drops)

Specialist / Hospital Use (Systemic Oral or Intravenous Formulations)

Oral and intravenous Fucithalmic (as sodium fusidate) are reserved, under specialist supervision, for more serious staphylococcal infections such as:

• Osteomyelitis and septic arthritis
• Endocarditis
• Deep-seated or severe skin and soft-tissue infections not responding to first-line therapy

Systemic Fucithalmic is always used in combination with another anti-staphylococcal antibiotic, because resistance develops rapidly when Fucithalmic is used alone for systemic infections.

Note: In many countries, including the United States, Fucithalmic topical/oral/IV products are not approved by the national regulator; availability and approved uses vary by country. Always follow the locally approved product label and your physician's advice.

Formulations of Fusidic Acid marketed in different countries include:

• Fusidic Acid cream/ointment - typically 2% w/w for topical skin application
• Fusidic Acid viscous eye drops - typically 1% w/w for ophthalmic use
• Fusidic Acid tablets (as sodium fusidate) - typically 250 mg for oral systemic use
• Sodium fusidate powder for intravenous infusion - for hospital/specialist use

Exact strength and available forms depend on the specific brand and market; check the product label.

Fucithalmic is a narrow-spectrum, steroid-structured antibacterial agent derived from the fungus Fusidium coccineum. Despite its steroid-like chemical backbone, it has no corticosteroid or hormonal activity. It works by inhibiting bacterial protein synthesis and is used mainly against Staphylococcus aureus, including many methicillin-resistant strains in some regions, though local resistance patterns vary.

Fucithalmic is most commonly used as a topical cream, ointment, or eye drop for localized staphylococcal skin and eye infections. Oral and injectable forms exist for more serious systemic staphylococcal infections but are reserved for specialist use in combination with other antibiotics.

Topical and Systemic Antibacterial Agent - Fucithalmic (Fusidane-class Antibiotic)

Mechanism of Action

Fusidic Acid inhibits bacterial protein synthesis by binding to bacterial elongation factor G (EF-G) and blocking its release from the ribosome after each cycle of peptide bond formation. This prevents the translocation step of protein translation, halting bacterial growth. Fusidic Acid is bacteriostatic at usual concentrations and can be bactericidal at higher local concentrations, such as those achieved with topical application.

Spectrum

Fusidic Acid is active mainly against Gram-positive bacteria, particularly Staphylococcus aureus (including many strains resistant to other antibiotic classes) and other staphylococci. It has limited activity against most Gram-negative organisms.

Pharmacokinetics (Systemic Use)

Oral Fusidic Acid is well absorbed, highly protein-bound, and penetrates well into bone, soft tissue, and abscess fluid, which supports its use in bone and joint infections. It is metabolized in the liver and excreted mainly in bile/feces, with a low proportion renally eliminated.

• Cream/ointment: Clean and dry the affected area, then apply a thin layer of Fucithalmic and gently rub in. Wash hands before and after application unless the hands are the treated area.
• Eye drops: Tilt the head back, pull down the lower eyelid, and instil one drop into the pocket formed. Avoid touching the dropper tip to the eye or any surface. Shake the bottle before use if directed on the label.
• Tablets: Swallow whole with a full glass of water, preferably with food to reduce stomach upset, at evenly spaced intervals as prescribed.
• Do not apply topical Fucithalmic to the eyes (unless using the specific eye drop formulation), open deep wounds, or mucous membranes unless directed by a physician.

Statins (e.g., simvastatin, atorvastatin) - Systemic Fucithalmic

Concomitant use of systemic (oral or intravenous) Fucithalmic with statins has been associated with a serious risk of rhabdomyolysis, in some cases fatal. This combination should generally be avoided; statin therapy is typically paused during a course of systemic Fucithalmic, under medical supervision. This interaction is not established for topical Fucithalmic, which has minimal systemic absorption.

Other Hepatically Metabolized Drugs (Systemic Use)

Systemic Fucithalmic may interact with other drugs metabolized by the liver (e.g., certain protease inhibitors), potentially altering blood levels of either drug. Inform your physician of all medicines you take before starting systemic Fucithalmic.

Topical Use

Clinically significant drug interactions are unlikely with topical Fucithalmic due to limited systemic absorption, but you should still inform your physician of all medicines and skin products you use.

Topical Use (Cream, Ointment, Eye Drops)

• Local burning, stinging, or itching at the application site
• Redness or mild skin irritation
• Contact dermatitis or allergic skin reaction (uncommon)
• Eye drops: transient stinging, blurred vision immediately after application

Oral / Intravenous Use

• Nausea, vomiting, abdominal discomfort, diarrhea
• Elevated liver enzymes and, uncommonly, jaundice (see Precautions and Warnings)
• Rash or hypersensitivity reactions
• Local irritation or thrombophlebitis at the intravenous infusion site

Seek medical attention if you notice severe rash, yellowing of the skin/eyes, or signs of a serious allergic reaction (swelling of the face/throat, difficulty breathing) while using Fucithalmic.

Pregnancy: Data on the use of Fucithalmic in pregnancy are limited. Topical Fucithalmic has minimal systemic absorption and is generally considered lower risk when used as directed, but systemic (oral/intravenous) Fucithalmic should be used only if clearly needed and the potential benefit justifies the potential risk to the fetus. Consult a physician before using Fucithalmic during pregnancy.

Breastfeeding: It is not well established whether Fucithalmic passes into breast milk in clinically significant amounts, particularly with topical use. As a precaution, avoid applying topical Fucithalmic directly on or near the nipple/breast area before breastfeeding, and consult a physician before using systemic Fucithalmic while breastfeeding.

• External use only for cream/ointment formulations of Fucithalmic; avoid contact with the eyes, nose, mouth, and mucous membranes unless a specific eye drop formulation is being used as directed.
• Antibiotic stewardship: Take/use Fucithalmic exactly as prescribed by your physician; do not stop, extend, skip doses, or share this medicine with others without medical advice.
• Limit duration of topical Fucithalmic use (typically 7-10 days) to reduce the risk of bacterial resistance; resistance to Fucithalmic can develop relatively easily, especially with prolonged or repeated courses used as monotherapy.
• Discontinue Fucithalmic and seek medical attention if the infection worsens, does not improve within a few days, or if signs of sensitization/allergic reaction develop.
• For systemic (oral/intravenous) Fucithalmic, periodic monitoring of liver function is recommended, particularly with prolonged courses or in patients with pre-existing liver disease, due to the risk of hepatotoxicity and jaundice.
• Use systemic Fucithalmic with caution in patients with hepatic impairment; dose adjustment or closer monitoring may be needed (see Use in Special Populations).
• Avoid concomitant use of systemic Fucithalmic with statins (see Drug Interactions).

Topical overdose of Fucithalmic is unlikely to cause serious harm beyond local skin irritation, but accidental ingestion of cream/ointment or excessive oral/intravenous dosing may cause gastrointestinal upset, or in severe cases, liver-related effects. If overdose of Fucithalmic is suspected, seek immediate medical attention or contact your local poison control/emergency services; do not attempt specific home treatment. Bring the product packaging with you if possible.

Store below 25°C, protected from light and moisture. Do not freeze. Keep out of reach of children. Discard any unused Fucithalmic eye drops 4-6 weeks after opening or as directed on the label.

Renal Impairment

Fucithalmic is eliminated mainly via the liver/bile, so dose adjustment is generally not required for renal impairment alone, but caution is advised in severe renal disease; consult a physician.

Hepatic Impairment

Systemic Fucithalmic should be used with caution in patients with liver disease, as it is hepatically metabolized and can rarely cause cholestatic jaundice or hepatotoxicity; dose reduction or avoidance may be necessary, and liver function should be monitored.

Elderly

No specific dose adjustment is generally required for topical Fucithalmic in elderly patients; systemic use should follow the same precautions as in adults, with attention to concurrent medications and hepatic function.

Children

Fucithalmic topical cream/ointment and eye drops are commonly used in children, including infants, for appropriate indications under medical guidance. Use of oral/intravenous Fucithalmic in children should be guided by a specialist, with weight-based dosing.

Topical Fucithalmic is typically used for 7-10 days; treatment beyond 2 weeks is generally not recommended without medical reassessment. Duration for systemic (oral/intravenous) Fucithalmic in serious infections (e.g., bone or joint infections) is longer and determined by the treating specialist based on clinical response.

Fusidane-class antibacterial (Fusidic Acid); steroid-structured (non-corticosteroid) antibiotic

Fusidic Acid inhibits bacterial protein synthesis by binding to elongation factor G (EF-G) and preventing its release from the ribosome, thereby blocking the translocation step required for peptide chain elongation. This halts bacterial growth (bacteriostatic effect) and can be bactericidal at higher concentrations.

Topical Fucithalmic (cream, ointment, eye drops) is used in children, including infants, for approved skin and eye infections, following the same application principles as in adults but under medical guidance, especially in neonates and young infants.

Systemic (oral/intravenous) Fucithalmic use in children should be directed and monitored by a specialist, with dosing calculated on a weight basis for serious staphylococcal infections; safety and efficacy data for unsupervised pediatric systemic use are limited, so it should not be used outside specialist care.